JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...
PARIS — In a study that employed change in inflammatory biomarkers as a primary endpoint, hair regrowth with ritlecitinib, a dual JAK3/TEC inhibitor, was observed across three types of cicatricial ...
PARIS — Long-term results from the ALLEGRO clinical trial program of Pfizer’s JAK inhibitor ritlecitinib for severe alopecia areata showed that complete scalp regrowth occurred in a good proportion of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results